Rotigotine ER is under clinical development by Luye Pharma Group and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rotigotine ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rotigotine ER overview
Rotigotine (LY-03003) is under development for the treatment of Parkinson’s disease. The drug candidate is administered through intramuscular route. It is developed as extended release formulation. The drug candidate acts by targeting dopamine D2 receptor.
Luye Pharma Group overview
Luye Pharma Group (Luye Pharma), a subsidiary of Luye Life Sciences Group Ltd, is a drug development company that discovers, manufactures, and commercializes novel formulations, generic drugs, and pharmaceutical products. The company offers its products in the form of tablets, formulations for injections, capsules, gels, anti-psychotic medicines, and modified-release dosages in the therapeutic areas of oncology, cardiovascular, orthopedics, hepatology, gastroenterology, gynecology, diabetes and central nervous system (CNS). Luye Pharma operates its R&D and manufacturing facilities in the US, China and Europe. The company exports products to Germany, the UK, Southeast Asia, the Middle East and North Africa. Luye Pharma is headquartered in Yantai, Shandong, China.
For a complete picture of Rotigotine ER’s drug-specific PTSR and LoA scores, buy the report here.